Xtl Biopharmaceuticals (XTLB) Long-Term Investments (2009 - 2015)

Xtl Biopharmaceuticals (XTLB) posted quarterly Long-Term Investments of $10000.0 for Q4 2015, down 99.49% on a QoQ basis from $2.0 million in Q2 2013.

Xtl Biopharmaceuticals (XTLB) Long-Term Investments (2009 - 2015) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Long-Term Investments for 5 consecutive years, with $10000.0 the latest figure, recorded in Q4 2015.

  • Quarterly Long-Term Investments changed N/A year-over-year to $10000.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $10000.0 (changed N/A YoY) and the FY2015 annual result came in at -$482000.0, changed N/A from the prior year.
  • Long-Term Investments eased to $10000.0 in Q4 2015 per XTLB's latest filing, from $2.0 million in the prior quarter.
  • Over the last five years, Long-Term Investments for XTLB reached as high as $2.2 million in Q1 2013 and fell as low as -$1.7 million in Q4 2012.
  • A 3-year average of $514400.0 and a median of $52000.0 in 2012 frame the typical range for Long-Term Investments.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 505,194.89
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.75 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 9.79 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Xtl Biopharmaceuticals 2.60 Bn 2.60 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2015 10,000.00
Jun 30, 2013 1.97 Mn
Mar 31, 2013 2.20 Mn
Dec 31, 2012 -1.66 Mn
Sep 30, 2012 52,000.00
Jun 30, 2010 179,000.00
Mar 31, 2010 156,000.00
Dec 31, 2009 135,000.00
Sep 30, 2009 95,000.00